Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.

导出 OA

翻译打印收藏纠错

第一作者： Charles J,Ryan

第一单位： Department of Medicine, Division of Hematology/Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA; Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA; Educational Concepts Group, LLC, Atlanta, Georgia, USA; Tulane Cancer Center, Departments of Medicine and Urology, Tulane Medical School, New Orleans, Louisiana, USA ryanc@medicine.ucsf.edu.

作者： Charles J,Ryan ^[1] ; Philip J,Saylor ^[2] ; Jason J,Everly ^[2] ; Oliver,Sartor ^[2]

作者单位： Department of Medicine, Division of Hematology/Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA; Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA; Educational Concepts Group, LLC, Atlanta, Georgia, USA; Tulane Cancer Center, Departments of Medicine and Urology, Tulane Medical School, New Orleans, Louisiana, USA ryanc@medicine.ucsf.edu. ^[1] Department of Medicine, Division of Hematology/Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA; Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA; Educational Concepts Group, LLC, Atlanta, Georgia, USA; Tulane Cancer Center, Departments of Medicine and Urology, Tulane Medical School, New Orleans, Louisiana, USA. ^[2]

关键词 Bone-metastatic castration-resistant prostate cancer Overall survival Pain Radium-223 Skeletal-related events